These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30468339)

  • 21. Evaluation of serum myeloperoxidase concentration in dogs with heart failure due to chronic mitral valvular insufficiency.
    Park JI; Suh SI; Hyun C
    Can J Vet Res; 2017 Jan; 81(1):37-40. PubMed ID: 28154461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma atrial natriuretic peptide is an early diagnosis and disease severity marker of myxomatous mitral valve disease in dogs.
    Ebisawa T; Ohta Y; Funayama M; Yamano S; Mizuno M; Mizuno T; Kasuya A; Sawada T; Lee J; Mizukoshi T; Uechi M
    Res Vet Sci; 2013 Jun; 94(3):717-21. PubMed ID: 23312500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic management of myxomatous mitral valve disease in dogs.
    Atkins CE; Häggström J
    J Vet Cardiol; 2012 Mar; 14(1):165-84. PubMed ID: 22386553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
    Bagardi M; Locatelli C; Zanaboni A; Galizzi A; Malchiodi D; Brambilla PG
    Pol J Vet Sci; 2021 Mar; 24(1):109-118. PubMed ID: 33847106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
    Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
    Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
    Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
    J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QT instability, an indicator of augmented arrhythmogenesis, increases with the progression of myxomatous mitral valve disease in dogs.
    Brüler BC; Jojima FS; Dittrich G; Giannico AT; Sousa MG
    J Vet Cardiol; 2018 Aug; 20(4):254-266. PubMed ID: 30031743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
    J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of natriuretic peptides in dogs with mitral valve disease.
    Tarnow I; Olsen LH; Kvart C; Hoglund K; Moesgaard SG; Kamstrup TS; Pedersen HD; Häggström J
    Vet J; 2009 May; 180(2):195-201. PubMed ID: 18675567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease.
    Menciotti G; Borgarelli M; Aherne M; Wesselowski S; Häggström J; Ljungvall I; Lahmers SM; Abbott JA
    J Vet Cardiol; 2017 Apr; 19(2):113-123. PubMed ID: 28279678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease.
    Ljungvall I; Rajamäki MM; Crosara S; Olsen LH; Kvart C; Borgarelli M; Höglund K; Häggström J
    Am J Vet Res; 2011 Aug; 72(8):1022-8. PubMed ID: 21801058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. R-R interval variations influence the degree of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Reimann MJ; Møller JE; Häggström J; Markussen B; Holen AE; Falk T; Olsen LH
    Vet J; 2014 Mar; 199(3):348-54. PubMed ID: 24507881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P; Saengklub N; Limprasutr V; Sawangkoon S; Kijtawornrat A
    J Vet Med Sci; 2017 Sep; 79(9):1480-1488. PubMed ID: 28717064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
    Winter RL; Saunders AB; Gordon SG; Miller MW; Fosgate GT; Suchodolski JS; Steiner JM
    Vet Clin Pathol; 2017 Jun; 46(2):299-307. PubMed ID: 28449360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
    J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma adrenomedullin concentration in dogs with myxomatous mitral valvular disease.
    Kanno N; Asano K; Teshima K; Seki M; Edamura K; Uechi M; Tanaka S
    J Vet Med Sci; 2012 Jun; 74(6):739-43. PubMed ID: 22240987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of serum cystatin-C and symmetric dimethylarginine concentrations in dogs with heart failure from chronic mitral valvular insufficiency.
    Choi BS; Moon HS; Seo SH; Hyun C
    J Vet Med Sci; 2017 Jan; 79(1):41-46. PubMed ID: 27725349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.